

**RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1649**

**PATENT**  
Attorney Docket No. 08702.0093-00000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
WOLFMAN *et al.* ) Group Art Unit: 1649  
)  
Application No.: 10/689,677 ) Examiner: Aditi Dutt  
)  
Filed: October 22, 2003 ) Confirmation No.: 2405  
)  
For: ACTRIIB Fusion Polypeptides and )  
Uses Therefor )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**REPLY TO FINAL OFFICE ACTION**

In reply to the Final Office Action mailed May 4, 2007, enclosed is a Petition for a One Month Extension and fee. Pursuant to 37 C.F.R. § 1.116, Applicants request amendment of this application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims beginning on page 4 of this paper.

**Remarks/Arguments** begin on page 9 of this paper.

**Attachments** to this amendment include:

- Declaration of Dr. Paul Yaworsky under 37 CFR § 1.132
- Ohsawa et al., J. Clin. Invest. 116:2924-2934 (2006)
- Alignment of amino acids 23-138 of SEQ ID NO:3 and amino acids 19-134 of SEQ ID NO:1
- Garg et al., Molecular and Cellular Endocrinology 153:169-181 (1999)